Vijaya Diagnostic Centre reported a robust 20.3% rise in profit at ₹1,730 million for FY26 on the back of strong volume growth and an integrated diagnostic model. Revenue grew by 19.5% to ₹8,142 million, with the company maintaining a strong 41.4% EBITDA margin. The Board has proposed a final dividend of ₹2 per share and announced plans to expand its network with 8-9 new hub centres in the coming year, underscoring a steady growth trajectory in the competitive diagnostics market.
Vijaya Diagnostic Reports Strong FY26 Growth With 20% Profit Jump
Profit After Tax: ₹1,730 million (up 20.3% YoY).
Consolidated Revenue: ₹8,142 million (up 19.5% YoY).
Reader Takeaway: Volume-led growth in the B2C segment drives margins, while aggressive network expansion remains a key performance variable.
What just happened
Vijaya Diagnostic Centre has released its FY26 financial results, showcasing significant growth across key metrics. The company reported a net profit of ₹1,730 million, compared to ₹1,438 million in the previous fiscal. Total income rose to ₹8,350 million, reflecting strong operational performance. Alongside the financial results, the Board recommended a final dividend of ₹2 per equity share and proposed an increase in the ESOP pool to 36,25,000 options to bolster talent retention.
Why this matters
The company’s reliance on the B2C segment, which contributes 92% of its revenue, remains a core strength. The expansion of EBITDA margins to 41.4% demonstrates the company’s ability to manage costs effectively while scaling. With 162 centres now operational, Vijaya Diagnostic is cementing its presence in existing markets like West Bengal and Pune, while doubling down on growth in Bengaluru.
Operational Highlights
Execution remained a priority in FY26, with 10 new hub centres commissioned. The company is actively investing in high-end diagnostic technology, including 3T MRI and PET-CT machines. Furthermore, digital transformation efforts and laboratory automation in hubs like Hyderabad (Panjagutta) are aimed at improving turnaround times and scalability.
What changes now
Management has outlined an ambitious roadmap for FY27, targeting the addition of 8-9 hub centres and 10-12 spoke centres. This continuous capital expenditure into the network is aimed at capturing a larger share of the shift toward preventive wellness diagnostics in India.
Risks to watch
Investors should be mindful of intensifying competition from both large national diagnostic chains and hospital-based laboratory networks. Additionally, the successful integration of new geographies remains critical. Talent attrition, specifically among specialized medical professionals, continues to be a standard operational risk within the sector.
What to track next
The primary focus for shareholders should be the successful execution of the FY27 expansion plan and the company's ability to maintain its margin profile amidst rising competitive pressures and costs associated with scaling.